Search Results - "Raga, M Gil"

Social support, coping strategies and sociodemographic factors in women with breast cancer by Calderon, C., Gomez, D., Carmona-Bayonas, A., Hernandez, R., Ghanem, I., Gil Raga, M., Ostios Garcia, L., Garcia Carrasco, M., Lopez de Ceballos, M. H., Ferreira, E., Jimenez-Fonseca, P.

“…Introduction The aim of this study was to analyze the associations between perceived social support and sociodemographic variables on coping strategies…”
Get full text

Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial by García Albéniz, X, Alonso, V, Escudero, P, Méndez, M, Gallego Plazas, J, Rodriguez, J R, Salud Salvia, A, Fernández-Plana, J, Manzano Alemany, H, Zanui, M, Falcó, E, Feliu Batlle, J, Gil-Raga, M, Fernández-Martos, C, Bohn Sarmiento, U, Alonso López, M C, Calderero Aragón, V, Rojo, F, Cuatrecasas, M, Maurel, J

Get full text

Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis by Gil-Raga, M., Jantus-Lewintre, E., Gallach, S., Giner-Bosch, V., Frangi-Caregnato, A., Safont-Aguilera, M. J., Garde-Noguera, J., Zorraquino-Pina, E., García-Martínez, M., Camps-Herrero, C.

“…Purpose After surgical resection, an ample prognosis variability among stages is observed. Multiple prognostic factors are individually studied and some CRC…”
Get full text

High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab by Garde-Noguera, J., Gil-Raga, M., Evgenyeva, E., García, J. A., Llombart-Cussac, A., Camps-Herrero, C.

“…Purpose To analyse the prognostic role of the immunohistochemical expression of pKDR in patients with advanced colorectal cancer treated with oxaliplatin and…”
Get full text

64P Integrative immune transcriptomic classification could improve patient selection for precision immunotherapy in advanced gastroesophageal adenocarcinoma by Cabeza Segura, M., Gambardella, V., Gimeno-Valiente, F., Carbonell-Asins, J.A., Alarcon-Molero, L., Gonzalez-Vilanova, A., Zuniga-Trejos, S., Rentero-Garrido, P., Villagrasa, R., Gil Raga, M., Richart, P., Huerta, M., Rosello Keranen, S., Roda Perez, D., Tarazona Llavero, N., Martínez-Ciarpaglini, C., Castillo, J., Cervantes, A., Fleitas, T.C.

Get full text

1432P Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients by Cabeza-Segura, M., Alarcón-Molero, L., Gambardella, V., Carbonell-Asins, J.A., Zuñiga, S., Gimeno-Valiente, F., Garzón-Lloría, Z., Gil Raga, M., Durá, A., Richart, P., Alonso, N., Villagrasa, R., Alfaro-Cervello, C., Peña, A., Huerta Alvaro, M., Tarazona, N., Martínez-Ciarpaglini, C., Cervantes, A., Castillo, J., Fleitas, T.

Get full text

1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients by Obispo, B., Hernandez, R., Cruz, P., Fernandez Montes, A., Gil Raga, M., Garcia, O.A., Rogado, J., Asensio-Martinez, E., Piera Molons, N., Pacheco-Barcia, V., López de Ceballos, M.H., Cano, J.M., Ostios Garcia, L., Antoñanzas Basa, M., Lorente, D., Manzano Fernández, A., Hernando Polo, S., Gonzalez Moya, M., Garcia, T., Calderon, C.

Get full text

P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study by Pacheco-Barcia, V., Hernandez Sangil, R., Fernández Montes, A., Cruz Castellanos, P., Castillo Trujillo, A., Rogado, J., Antoñanzas, M., Gil Raga, M., Manzano, A., Asensio, H., Lorente, D., Obispo, B., Ostios, L., López de Ceballos, M., Valero Arbizu, M., García Carrasco, M., Maria Cano, J., Piera, N., Carmona-Bayonas, A., García, T., Calderón, C.

Get full text

POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers by Fernandez, M E Elez, Gómez-España, M.A., Grávalos, C., García-Alfonso, P., Rodríguez, B., Losa, F., Ales-Diaz, I.C., Suarez, B Graña, Toledano, M., Valladares-Ayerbes, M., Marques, E Polo, Fernandez, M Salgado, de Castro, E Martínez, Raga, M Gil, Salvia, M A Salud, Ruiz-Casado, A., Rodríguez-Ariza, A., Aguilar, E Aranda

Get full text

585P - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers by Fernandez, M E Elez, Gómez-España, M.A., Grávalos, C., García-Alfonso, P., Rodríguez, B., Losa, F., Ales-Diaz, I.C., Suarez, B Graña, Toledano, M., Valladares-Ayerbes, M., Marques, E Polo, Fernandez, M Salgado, de Castro, E Martínez, Raga, M Gil, Salvia, M A Salud, Ruiz-Casado, A., Rodríguez-Ariza, A., Aguilar, E Aranda

“…Biomarkers associated to antiangiogiogenic agents in metastatic colorectal cancer (mCRC) have not yet been validated Here we present the efficacy and safety…”
Get full text

585PPOLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers by Fernandez, M E Elez, Gómez-España, M A, Grávalos, C, García-Alfonso, P, Rodríguez, B, Losa, F, Ales-Diaz, I C, Suarez, B Graña, Toledano, M, Valladares-Ayerbes, M, Marques, E Polo, Fernandez, M Salgado, de Castro, E Martínez, Raga, M Gil, Salvia, M A Salud, Ruiz-Casado, A, Rodríguez-Ariza, A, Aguilar, E Aranda

“…Abstract Background Biomarkers associated to antiangiogiogenic agents in metastatic colorectal cancer (mCRC) have not yet been validated Here we present the…”
Get full text

486PProspective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial by García Albéniz, X, Alonso, V, Escudero, P, Méndez, M, Gallego Plazas, J, Rodriguez, J R, Salud Salvia, A, Fernández-Plana, J, Manzano Alemany, H, Zanui, M, Falcó, E, Feliu Batlle, J, Gil-Raga, M, Fernández-Martos, C, Bohn Sarmiento, U, Alonso López, M C, Calderero Aragón, V, Rojo, F, Cuatrecasas, M, Maurel, J

Get full text

Impact on survival of pulmonary metastasectomy in colorectal cancer by Meri Abad, M., Avila Andrade, C., Cunquero Tomas, A.J., Rodriguez Huaman, A., Fernandez Diaz, A.B., Condori Farfan, L., Shaheen, I., Safont Aguilera, M.J., Caballero Diaz, C., Iranzo Gonzalez-Cruz, V., Blasco Cordellat, A., Godes Sanz de Bremond, M.C., Berrocal, A., Sforza, V., Gil Raga, M., Camps Herrero, C.

Get full text

70-gene signature, an encouraging prognostic tool to guide adjuvant therapy in early breast cancer by Cunquero Tomas, A., Avila Andrade, C., Fernandez Diaz, A.B., Meri Abad, M., Shaheen, I., Condori Farfan, L., Rodriguez Huaman, A., Sforza, V., Aparisi Aparisi, F.D.A., Safont Aguilera, M.J., Blasco Cordellat, A., Gil Raga, M., Caballero Diaz, C., Berrocal, A., Godes Sanz de Bremond, M.C., Pérez, A., Iranzo Gonzalez-Cruz, V., Camps Herrero, C.

Get full text

P-272 Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab by García Alfonso, P., Ortiz, M.J., Durán, G., Falcó, E., Muñoz, A., García-Paredes, B., Salgado, M., López-Ladrón, A., Vieitez de Prado, J.M., Valladares, M., Salud, A., Guillén-Ponce, C., Lopez, R., Robles, L., Juárez, A., Serrano, S., Montagut, C., Zanui, M., Gil Raga, M., La Casta, A., Benavides, M., Aranda, E.

Get full text

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study by Sastre, J., García-Alfonso, P., Viéitez, J.M., Cano, M.T., Rivera, F., Reina-Zoilo, J.J., Salud-Salvia, A., Quintero, G., Robles-Díaz, L., Safont, M.J., La Casta, A., Gil, S., Polo, E., Asensio-Martínez, E., García-Paredes, B., López, R.L., Guillot, M., Valladares-Ayerbes, M., Aranda, E., Díaz-Rubio, E., Viéitez, J.M., Jiménez, P., Aguilar, E. Aranda, Gómez, A., Gil Calle, S., Salud, A., Valladares, M., Graña, B., García-Alfonso, P., Rivera, F., Quintero, G., Reina, J.J., González Flores, E., Salgado, M., Grande, E., Guillén, C., Garcia Carbonero, R., Flor, M.J., Safont, M.J., La Casta, A., Arévalo, S., Sastre, J., López López, R., Manzano, H., Guillot, M., Hernández Yagüe, X., Arrivi, A., Falcó, E., Gallego, J., Escudero, P., Cabezas, I., Juárez, A., Gálvez, E., Grávalos, C., Robles, L., Polo, E., Dueñas, R., Campos, J.M., Albert, A., Salinas, P., Montagut, C., Provencio, M., Ruiz Casado, A., Muñoz, J., Gil Raga, M., Chilet, M.R., González González, F.J., Massutí, B., López, A., Aparicio, J., Marín, M., Alfaro, J., Zanui, M., Gutiérrez Abad, D., García Tapiador, A.M., García-Girón, C., Molina Saera, J., Torres Sánchez, E., López, I., Bosch, C., Valero, J., Martínez de Prado, P.

“…We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan…”
Get full text